The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
jiao zhi mu xi bao liu fen zi ba xiang zhi liao yan jiu jin zhan
Author(s): 
Pages: 586-590
Year: Issue:  6
Journal: Journal of International Neurology and Neurosurgery

Keyword: 
Abstract: 胶质母细胞瘤(glioblastoma,GBM)的分子靶向治疗是目前研究的热点.大量针对GBM进行分子靶向治疗的临床研究相继开展,部分靶向药物如贝伐单抗、西地尼布、西仑吉肽、恩扎妥林和尼妥珠单抗已完成了Ⅲ期临床试验.大部分Ⅲ期临床试验未得出预想的阳性结果,然而,研究结果也显示某些特定的亚型能从靶向治疗中获益.未来的研究应充分考虑到GBM的异质性,转变试图以一种靶向药物治疗所有GBM的观念.寻找能预测特定靶向治疗效果的分子标记物,在基因和分子分型的基础上进行个体化的精准靶向治疗.
Related Articles
No related articles found